As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed – FierceBiotech
FierceBiotech |
As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed
FierceBiotech It's been a big week for CAR–T: Novartis, Juno, Kite, Bluebird Bio and Nanjing Legend Biotech all posted positive data for the cutting-edge experimental cancer class at ASCO, and now Novartis has revealed the long-awaited interim Juliet data for its … Novartis touts new T–cell therapy data in race for FDA approval Novartis' CAR–T stacks up to Kite in lymphoma Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL |
